A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer

A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer

Abstract Background Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease with different subtypes, multidisciplinary teams-led management, and a poor prognosis. Currently, the clinical benefits of stage III NSCLC in the neoadjuvant setting are still unclear. We performed a meta-ana...

Full description

Bibliographic Details
Main Authors: Wei Liu, Tiantian Zhang, Qian Zhang, Li Li, Chunhua Xu
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Pulmonary Medicine
Subjects:
Neoadjuvant chemoimmunotherapy
Non-small cell lung cancer
Stage III
Safety and efficacy
Online Access:https://doi.org/10.1186/s12890-022-02292-5

Internet

https://doi.org/10.1186/s12890-022-02292-5

Similar Items